Introduction
Lymphadenopathy is a reported complication of phenytoin therapy.`-3 Quinidine bisulphate, a commonly used antiarrhythmic agent, may also lead to lymphadenopathy through the induction of lupus erythematosus.4 '5 We describe a patient with quinidine-induced acute lymphadenopathy syndrome proven by rechallenge of the drug and in whom serum markers for systemic lupus were negative. To our knowledge, this is the first confirmed case of direct quinidine-induced lymphadenopathy.
Case report
A 53 year old man gave a history of paroxysmal palpitations on irregular treatment with digoxin which was stopped 1 month ago. When first seen, he was found to be in atrial fibrillation with a controlled ventricular rate of 98/min. He gave no history suggestive of thyrotoxicosis nor ischaemic heart disease, and he was a non-drinker. Examination showed a blood pressure of 120/180 mmHg, and no evidence of valvular disease. An echocardiogram showed normal mitral valve and a left atrial dimension of 3.5 cm in the long axis view. The thyroid function was normal.
An elective direct current cardioversion was planned after a course of intravenous heparin. Although external shocks of 200 J resulted in conversion into sinus rhythm, the latter was unstable and reverted back to atrial fibrillation. A course of quinidine bisulphate 500 mg b.d. and warfarin was commenced, and sinus rhythm returned after the third dose of quinidine.
He was discharged but 4 days later he developed fever, skin rash and tender lymphadenopathy. The left supraclavicular lymph node was enlarged to 1.5 x 2 cm, and painful 2 x 2 cm large lymp. nodes were found in both axillae. Multiple tende inguinal lymph nodes (< 1 cm) were palpable. i maculopapular rash developed over the trunl which spread to the upper limbs. There was n hepatosplenomegaly. Investigations showed normal haemoglobin, white cell count, differentie and platelet count. The renal and liver functioi tests were normal. Antinuclear factor was negativ and complement 3 and 4 levels were within th normal limits. Serology tests for Epstein-Bar virus, rubella virus, cytomegalovirus, adenoviru and toxoplasma were negative. The rash an, lymphadenopathy subsided 4 days after discon tinuation of quinidine.
In view of the possibility of an intercurrent vira infection as the cause of the lymphadenopathy, th patient was admitted for repeat treatment wit] quinidine. A similar skin rash and fever develope within 12 hours of 500 mg of quinidine, withou lymphadenopathy. The medication was stoppe immediately and the patient was subsequentl controlled on flecainide acetate.
Discussion
Apart from reactions to drugs, lymphadenopath can complicate infection, serum sickness an' connective tissue disease. The hypersensitivit reaction to phenytoin is well known, with lympha denopathy occurring either at the start of dru treatment3 or developing after months of therapy While self limiting, cases of fatal lymphomas hav been reported to occur months after cessation o treatment.6
To our knowledge, there is only one previou published report of an association betweei lymphadenopathy and quinidine.7 The patient con cerned developed anaemia and lymphadenopathafter 3 years' treatment with quinidine sulphatc which subsided on withdrawal of the medication Rechallenge was not performed in that stud) although a lymph node biopsy showed reactive, atypical follicular hyperplasia. However, a direct causal relationship between quinidine and lymphadenopathy in that study was questioned.8 The symptoms and signs reported were suggestive of drug-induced systemic lupus erythematosus, of which quinidine is a well recognized cause,3'4 which was not excluded by relevant serological data in that study. In our patient the serological tests for lupus were negative on both occasions when quinidine was prescribed. Although lymphadenopathy was not detected in the rechallenge after one dose of quinidine, the typical acute febrile illness and skin rash were remarkably similar to the first occasion, and we felt that further treatment with quinidine could not be justified.
Thus an acute lymphadenopathy syndrome can occur after quinidine therapy. The reactions appeared to be self limiting and did not require the induction of lupus erythematosus.
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